Oral Antianginal Agents Market
Number of pages: 100 | Report Format: PDF | Published date: June 09, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
5.4% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global oral antianginal agent is expected to register a revenue CAGR of 5.4% during the forecast period.
Oral Antianginal Agents Market Fundamentals
Antianginal medications are used to treat angina symptoms and stop heart attacks. The patient's chance of having a heart attack or stroke is crucial; nevertheless, the risk should be able to be decreased with the help of medicine and a change in lifestyle. According to guidelines, secondary prevention of cardiovascular disease should begin with one or two antianginal medications, aspirin, perhaps an ACE inhibitor, and a statin. Additionally, calcium channel blockers and beta-blockers are the antianginal medications that are advised for first therapy. These medications decrease myocardial ischemia through heart rate lowering and vasodilatory processes, respectively. A doctor typically recommends one or both of these medication types and a short-acting nitrate to treat angina episodes quickly. Alternative antianginal treatments, such as oral long-acting nitrates and newer antianginal medications, are available if these medications are not tolerated, are contraindicated, or do not alleviate symptoms.
For the treatment of angina, beta-blockers, including metoprolol, atenolol, and propranolol, are frequently recommended. By preventing the effects of adrenaline, these drugs reduce the burden on the heart and thus lower blood pressure and heart rate. Beta-blockers are used to prevent angina episodes over the long term and can increase exercise tolerance. However, Amlodipine, verapamil, and diltiazem are calcium channel blockers that relax the blood arteries and lessen the burden on the heart by blocking calcium channels. They can be used for long-term prophylaxis as well as for the effective relief of angina symptoms.
Nitrates have traditionally been thought to impact myocardial demand by lowering the left ventricle's filling pressure and intraventricular volume. They have been used more frequently to increase coronary blood flow, cause coronary vasodilation, and impact endothelial competence to enhance oxygen delivery in myocardial ischemia. Several different nitrates can be used to treat chronic, stable angina. Long-acting drugs are helpful as monotherapy for moderate angina and as a complementary therapy for more severe types, whereas short-acting drugs are appropriate for acute episodes and preventative measures.
Oral Antianginal Agents Market Dynamics
During the forecast period, it is anticipated that the prevalence of Raynaud's syndrome, pulmonary hypertension, high blood pressure, heart failure, heart attacks, esophageal spasms, cyanide poisoning, angina pectoris prophylaxis, angina, anal fissure, and fistula would increase. According to the U.S. Department of Health & Human Services, in the United States, in 2021, hypertension was a major or leading factor in 691,095 deaths. A systolic blood pressure above 130 mmHg, a diastolic blood pressure over 80 mmHg, or needing medication to control hypertension are all considered hypertension symptoms, affecting over half of Americans, or 116 million individuals. 24% of persons with hypertension have their disease under control, which is just roughly 1 in 4 cases. 140/90 mmHg or higher blood pressure was seen in around half (45%) of persons with uncontrolled hypertension, 37 million American adults were included in this.
The increase in patients with cardiac illnesses, including coronary heart disease, is one of the main factors fueling the market's expansion. For instance, according to information provided by the World Health Organization, ischemic heart disease was the top cause of death worldwide in December 2020, accounting for 16% of all fatalities. The number of fatalities from this illness has increased significantly since 2000, from 8.9 million in 2000 to more than 2 million in 2019. With around 11% and 6% of all fatalities, stroke and chronic obstructive pulmonary disease (COPD) are the second and third leading causes of mortality. According to an article published "Angina: Contemporary Diagnosis and Management," that was published in PubMed Central in February 2020, ischemic heart disease (IHD) continues to be the main cause of adult death and years of life lost, particularly among women under the age of 55. Therefore, during the course of the projected period, the market growth for antianginal medications is projected to be driven by the rising number of patients with IHD. For instance, according to the National Center for Biotechnology Information 2020, IHD affects about 126 million people worldwide (1,655 per 100,000), or about 1.72% of the total population. IHD caused nine million deaths worldwide. Men were more frequently afflicted than women, and age-related increases in frequency were generally seen starting in the fourth decade. The prevalence of IHD is increasing worldwide. By 2030, it is predicted that the current prevalence rate of 1,655 per 100,000 people will have risen to 1,845 or higher.
Oral Antianginal Agents Market Ecosystem
The global oral antianginal agent market is analyzed from the following perspectives by drug class, distribution channel, and region.
Oral Antianginal Agents Market by Drug Class
Based on the drug class, the global oral antianginal agent market is segmented into β-blockers, calcium channel blockers, long-acting nitrates, and others.
The β-blockers segment showed significant growth during the forecast period with a revenue CAGR of 5.1%. The market is expected to grow over the next years as a result of rising cardiovascular illness incidence and an increase in the elderly population. Beta-blockers are helpful in reducing the symptoms of some types of migraine and anxiety. Beta-blockers have seen a surge in interest and investment as a result, which is fueling the expansion of the industry. Pharmaceutical firms are spending a lot of money on research and development to develop innovative beta blockers that are more effective, safe, and tolerable. To increase their market share, these corporations are also creating combination medications.
The calcium channel blockers segment showed lucrative growth during the forecast period. The market for calcium channel blockers is predicted to develop faster than average due to the rising prevalence of cardiovascular disorders and people's changing lifestyles. One of the main factors leading to heart disease is hypertension, often known as high blood pressure. Another aspect of the market's expansion is the rise in heart disease. For instance, heart failure is a chronic, incapacitating cardio-renal-metabolic condition that affects at least 60 million people globally, according to a news release published by Boehringer Ingelheim GmbH in August 2021. New treatment solutions are badly required as heart failure prevalence rises. Global demand for the medications available to treat hypertension resulted, which is driving the expansion of the segment.
Oral Antianginal Agents Market by Distribution Channel
Based on the distribution channel, the globaloral antianginal agent market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Due to the rise in demand for antianginal drugs at hospital pharmacies, which are used to treat a range of indications, including cardiovascular disorders and hypertension, the hospital pharmacies segment is predicted to dominate the market throughout the projection period. For instance, Amrita Hospital in Haryana, billed as India's largest private hospital with 2,600 beds, was opened in August 2022 by Prime Minister Narendra Modi. It is anticipated that as there are more major hospitals, patient care will improve, ultimately accelerating the hospital pharmacies segment's growth.
Oral Antianginal Agents Market by Region
Based on the region, the global oral antianginal agent market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is likely to dominate the market during the forecast period. The adoption of a sedentary lifestyle has negative effects on people's health and is known to contribute to conditions such as high blood pressure, and cardiovascular illnesses. For instance, according to the Pan American Health Organization (PAHO), ischemic heart disease and stroke were the region's main causes of death, and a leading cause of mortality and disability globally is cardiovascular disease (CVD). Additionally, according to the same source, ischemic heart disease, which accounts for 73.6 deaths per 100,000 persons, is substantial. Cardiovascular ailments in the Americas account for 40.8 million disability-adjusted life years (DALYs) annually. So, it is anticipated that the use of oral antianginal agents will grow in order to reduce such high mortality. In the near future, this is anticipated to accelerate market expansion. Furthermore, Due to its well-established healthcare system, rising use of medicines, and concentration of major producers, North America has the lion's share of the global market for oral antianginal agents.
In the upcoming years, it is expected that Asia Pacific will experience substantial growth due to the rising prevalence of cardiovascular diseases and improved healthcare infrastructure; the Asia Pacific area offers a sizable market potential for the oral antianginal agent industry. For instance, the primary cause of mortality is cardiovascular disease (CVD), which includes ischemic heart disease and cerebrovascular conditions like stroke. According to the World Health Organization, India is responsible for one-fifth of all global deaths, particularly among the younger population. According to the analysis of the Global Burden of Disease research, India has an age-standardized CVD mortality rate of 272 per 100,000 people, much higher than the global average of 235.
Oral Antianginal Agents Market Competitive Landscape
Some of the prominent market players in the global oral antianginal agent market include,
Oral Antianginal Agents Market Strategic Development
Antianginal medications are used to treat angina symptoms right away and stop attacks from happening.
The revenue CAGR of the oral antianginal agent market during the forecast period will be 5.4%.
Some of the prominent market players in the global oral antianginal agent market include Novartis AG, Pfizer, Inc., and Boehringer Ingelheim.
North America is dominating the global oral antianginal agent market.
The beta blockers segment led the global oral antianginal agent market.
*Insights on financial performance are subject to the availability of information in the public domain